Bladder Cancer Coverage from Every Angle

Camrelizumab Treatment in Upper Tract Urothelial Carcinoma: Case Report

By: Kayci Reyer
Posted: Tuesday, July 6, 2021

A case report presented in Translational Andrology and Urology described the results of treatment with the novel PD-1 inhibitor camrelizumab in a patient with upper tract urothelial carcinoma. Gonghui Li, MD, PhD, of the Zhejiang University School of Medicine in China, and colleagues reported the effects of camrelizumab when used as a salvage treatment due to the intolerable toxicity of chemotherapy.

The patient, an 80-year-old woman, had been diagnosed with localized upper tract urothelial carcinoma (pT4N0M0). She was initially treated with radical nephroureterectomy but experienced relapse 2 months after the procedure. Because her advanced age and renal impairment rendered her ineligible to receive chemotherapy, the patient underwent genetic testing, which revealed a strong positive expression of PD-L1 and a high tumor mutational burden. She began receiving salvage camrelizumab therapy at 200 mg once every 3 weeks.

After five treatment cycles, the tumor was noted to have decreased in diameter; after eight cycles, a partial response was achieved. However, the tumor diameter was found to have increased after 11 cycles, and disease progression was noted at the conclusion of cycle 14. The patient then began receiving a combination of camrelizumab and the tyrosine kinase inhibitor anlotinib, undergoing follow-up on an ongoing basis.

“This case report showed that single camrelizumab may provide an alternative option for patients with recurrent [upper tract urothelial carcinoma] after [radical nephroureterectomy], and there may be a positive connection between PD-L1 expression and the response rate to therapy with PD-L1 inhibitors,” concluded the authors.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.